About this trial

The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode threads that are implanted in the brain by the R1 Robot, a robotic electrode thread inserter.

Eligibility criteria

Qualifiers

Severe quadriplegia (tetraplegia) due to spinal cord injury or amyotrophic lateral sclerosis (ALS) for at least 1 year without improvement, where quadriplegia is defined as having very limited or no hand, wrist, and arm movement and all levels below

Life expectancy ≥ 12 months.

Ability to communicate in English

Presence of a stable caregiver

Disqualifiers

Moderate to high risk for serious perioperative adverse events

Active implanted devices

Morbid obesity (Body Mass Index > 40)

History of poorly controlled seizures or epilepsy

Trial design

Treatments tested in this trial

  • N1 Implant
  • R1 Robot

Treatment groups

15 Participants
are divided into 1 treatment group

Locations

2
Barrow Neurological Institute85013, PhoenixArizona, United States
University of Miami33136, MiamiFlorida, United States

Sponsors and collaborators

Neuralink Corp

Lead sponsor